{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:41:20Z","timestamp":1771015280831,"version":"3.50.1"},"reference-count":165,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Discovery"],"published-print":{"date-parts":[[2015,7,3]]},"DOI":"10.1517\/17460441.2015.1045295","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T09:41:58Z","timestamp":1434534118000},"page":"791-808","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["The preclinical discovery of rituximab for the treatment of non-Hodgkin\u2019s lymphoma"],"prefix":"10.1517","volume":"10","author":[{"given":"Piotr","family":"Smolewski","sequence":"first","affiliation":[{"name":"Medical University of Lodz, Department of Experimental Hematology","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Medical University of Lodz, Copernicus Memorial Hospital, Department of Hematology","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,6,17]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-13150-4_1"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2014.1.481"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2013.07.014"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6965328"},{"key":"e_1_3_2_8_1","first-page":"3147","article-title":"Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen","volume":"40","author":"Nadler LM","year":"1980","unstructured":"Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980;40:3147-54","journal-title":"Cancer Res"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198203043060906"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.6.1766"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.2.584.584"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.139.10.3521"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0303-269"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1110"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04683.x"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/biot.200800110"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02720.x"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.404178"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1314"},{"issue":"6","key":"e_1_3_2_22_1","first-page":"9","article-title":"Rituximab: an insider\u2019s historical perspective","volume":"27","author":"Grillo-L\u00f3pez AJ","year":"2000","unstructured":"Grillo-L\u00f3pez AJ. Rituximab: an insider\u2019s historical perspective. Semin Oncol 2000;27(6 Suppl 12):9-16","journal-title":"Semin Oncol"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(00)90059-3"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.146"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50025"},{"key":"e_1_3_2_27_1","first-page":"29","article-title":"Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab)","volume":"31","author":"Nishida M","year":"2007","unstructured":"Nishida M, Usuda S, Okabe M, et al. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Int J Oncol 2007;31:29-40","journal-title":"Int J Oncol"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-001-0247-1"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.11.4220"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1997.12.177"},{"key":"e_1_3_2_31_1","first-page":"1763","article-title":"Clinical status and optimal use of rituximab for B-cell lymphomas","volume":"12","author":"McLaughlin P","year":"1998","unstructured":"McLaughlin P, White CA, Grillo-L\u00f3pez AJ, Maloney DG. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) 1998;12:1763-9","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/74704"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052283"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-135160"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3324\/haematol.2011.047159","article-title":"The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden","volume":"96","author":"Boross P","year":"2011","unstructured":"Boross P, Jansen JH, de Haij S, et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 2011;96:1822-30","journal-title":"Haematologica"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119616"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.3.1109"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.013"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-009480"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-272765"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431825"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1089\/108497802320970226"},{"key":"e_1_3_2_45_1","first-page":"1183","article-title":"Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin\u2019s lymphoma B cell lines to paclitaxel-induced apoptosis","volume":"2","author":"Jazirehi AR","year":"2003","unstructured":"Jazirehi AR, Gan XH, De Vos S, et al. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin\u2019s lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003;2:1183-93","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402559"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208954"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-009-0337-7"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050016"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu046"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-006-6314-5"},{"key":"e_1_3_2_52_1","first-page":"2961","article-title":"Potentiation of fludarabine cytotoxicity on non-Hodgkin\u2019s lymphoma by pentoxifylline and rituximab","volume":"20","author":"Alas S","year":"2000","unstructured":"Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin\u2019s lymphoma by pentoxifylline and rituximab. Anticancer Res 2000;20:2961-6","journal-title":"Anticancer Res"},{"key":"e_1_3_2_53_1","first-page":"2143","article-title":"Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells","volume":"119","author":"Ivanov A","year":"2009","unstructured":"Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009;119:2143-59","journal-title":"J Clin Invest"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.5.1765.h81702001765_1765_1773"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903349688"},{"key":"e_1_3_2_56_1","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow KU","year":"2002","unstructured":"Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002;87:33-43","journal-title":"Haematologica"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2013.1557"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404959"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12452"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000008"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-5-103"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.823492"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-129833"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.1693.3.12"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.5604\/17322693.1078386"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2014.2405"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0260-5"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/13693780400007151"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-303354"},{"issue":"14","key":"e_1_3_2_70_1","first-page":"00259","article-title":"Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies","volume":"0161","author":"Shor B","year":"2014","unstructured":"Shor B, Gerber HP, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol 2014;S0161-5890(14):00259-4","journal-title":"Mol Immunol"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543781003703694"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1455"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2015.989020"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107011"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.5604\/17322693.1130704"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4405"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06841.x"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.8387"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05286.x"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/265840"},{"issue":"4","key":"e_1_3_2_82_1","first-page":"iv128","article-title":"High response rates with lenalidomide plus rituximab for untreated indolent B cell non-Hodgkins lymphoma","volume":"22","author":"Fowler N","year":"2011","unstructured":"Fowler N, Hagemeister F, Mclaughlin P, et al. High response rates with lenalidomide plus rituximab for untreated indolent B cell non-Hodgkins lymphoma. Ann Oncol 2011;22(Suppl 4):iv128-9","journal-title":"Ann Oncol"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0905"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12541"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-455691"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.1862"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23919"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13052"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000362"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2012.5847.x"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204577"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21778"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70005-1"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37850"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12111"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50033"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23674"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1219"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1219"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70122-0"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.9493"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.137"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.191"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70191-3"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2103-3"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523845"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23668"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4556"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_3_2_121_1","first-page":"489","article-title":"Phase 1\/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"115","author":"Byrd JC","year":"2010","unstructured":"Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1\/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Br J Haematol 2010;115:489-95","journal-title":"Br J Haematol"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70335-3"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.100818"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090597"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60313-X"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70481-3"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2012.665444"},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2014.963048"},{"key":"e_1_3_2_130_1","first-page":"569","article-title":"Non-clinical pharmacokinetic\/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab","volume":"6411","author":"Bittner B","year":"2014","unstructured":"Bittner B, Richter WF, Hourcade-Potelleret F, et al. Non-clinical pharmacokinetic\/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab. Drug Res (Stuttg) 2014;6411:569-75","journal-title":"Drug Res (Stuttg)"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2631"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200311000-00006"},{"key":"e_1_3_2_133_1","doi-asserted-by":"publisher","DOI":"10.1089\/15258160151135088"},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008389119525"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf155"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.171"},{"key":"e_1_3_2_138_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000184162.60197.c1"},{"key":"e_1_3_2_139_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_3_2_140_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674"},{"key":"e_1_3_2_141_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"e_1_3_2_142_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-005-5882-3"},{"key":"e_1_3_2_143_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2014.07.004"},{"key":"e_1_3_2_144_1","doi-asserted-by":"publisher","DOI":"10.1159\/000368291"},{"key":"e_1_3_2_145_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12695"},{"key":"e_1_3_2_146_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6400"},{"key":"e_1_3_2_147_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3187"},{"key":"e_1_3_2_148_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.681657"},{"key":"e_1_3_2_149_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08966.x"},{"key":"e_1_3_2_150_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0493"},{"key":"e_1_3_2_151_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428191003672123"},{"key":"e_1_3_2_152_1","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2015.988944"},{"key":"e_1_3_2_153_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.28282"},{"key":"e_1_3_2_154_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.911859"},{"key":"e_1_3_2_155_1","first-page":"1","article-title":"Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy","volume":"8","author":"Kahl BS","year":"2010","unstructured":"Kahl BS, Cheson BD, Friedberg JW. Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. Clin Adv Hematol Oncol 2010;8:1-16","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_3_2_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.06.005"},{"key":"e_1_3_2_157_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108455108"},{"key":"e_1_3_2_158_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2012.668881"},{"key":"e_1_3_2_159_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1182"},{"key":"e_1_3_2_160_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0340-3"},{"key":"e_1_3_2_161_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.14"},{"key":"e_1_3_2_162_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.146"},{"key":"e_1_3_2_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.04.063"},{"key":"e_1_3_2_164_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S45957"},{"key":"e_1_3_2_165_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.65"},{"key":"e_1_3_2_166_1","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-015-0359-8","article-title":"Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin\u2019s lymphoma","author":"Keating GM","year":"2015","unstructured":"Keating GM. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin\u2019s lymphoma. Target Oncol 2015. [Epub ahead of print]","journal-title":"Target Oncol"},{"key":"e_1_3_2_167_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.12"}],"container-title":["Expert Opinion on Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/17460441.2015.1045295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:03:45Z","timestamp":1770419025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/17460441.2015.1045295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,17]]},"references-count":165,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7,3]]}},"alternative-id":["10.1517\/17460441.2015.1045295"],"URL":"https:\/\/doi.org\/10.1517\/17460441.2015.1045295","relation":{},"ISSN":["1746-0441","1746-045X"],"issn-type":[{"value":"1746-0441","type":"print"},{"value":"1746-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}